Advanced Enzyme Technologies 향후 성장

Future 기준 점검 2/6

Advanced Enzyme Technologies (는) 각각 연간 15% 및 15.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 15% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 12.1% 로 예상됩니다.

핵심 정보

15.0%

이익 성장률

15.01%

EPS 성장률

Chemicals 이익 성장	19.2%
매출 성장률	15.8%
향후 자기자본이익률	12.05%
애널리스트 커버리지	Low
마지막 업데이트	14 Nov 2025

최근 향후 성장 업데이트

Recent updates

Preventive Health And Green Chemistry Will Expand Future Markets

Aug 17Key Takeaways Expansion into health, wellness, and sustainable enzymatic solutions, along with new B2C initiatives, positions for growth and improved margins as consumer demand rises. International diversification, R&D investment, and increased capacity utilization support long-term product differentiation, earnings stability, and operating leverage.

Here's What's Concerning About Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital

Aug 04

After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar

Aug 20

We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now

Jul 19

Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00

Jul 13

Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business

Apr 08

Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends

Sep 23

Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital

Feb 03

Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends

Aug 11

With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting

May 13

Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture

Mar 28

The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?

Mar 13

Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)

Feb 21

Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 18

I Built A List Of Growing Companies And Advanced Enzyme Technologies (NSE:ADVENZYMES) Made The Cut

Feb 03

What Kind Of Investors Own Most Of Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)?

Jan 19

What Do The Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Tell Us?

Dec 28

The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 114%, So Why Not Pay It Some Attention?

Dec 13

Have Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Insiders Been Selling Their Stock?

Nov 28

이익 및 매출 성장 예측

NSEI:ADVENZYMES - 애널리스트 향후 추정치 및 과거 재무 데이터 (INR Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
3/31/2028	10,343	2,125	827	1,771	1
3/31/2027	8,911	1,807	919	1,484	1
3/31/2026	7,507	1,563	1,450	1,731	1
9/30/2025	7,067	1,474	1,323	1,643	N/A
6/30/2025	6,683	1,369	N/A	N/A	N/A
3/31/2025	6,369	1,311	1,077	1,425	N/A
12/31/2024	6,275	1,329	N/A	N/A	N/A
9/30/2024	6,194	1,371	904	1,422	N/A
6/30/2024	6,311	1,386	N/A	N/A	N/A
3/31/2024	6,239	1,333	941	1,414	N/A
12/31/2023	6,048	1,371	N/A	N/A	N/A
9/30/2023	5,859	1,248	965	1,327	N/A
6/30/2023	5,668	1,166	N/A	N/A	N/A
3/31/2023	5,406	1,056	1,022	1,404	N/A
12/31/2022	5,337	979	N/A	N/A	N/A
9/30/2022	5,251	960	806	1,164	N/A
6/30/2022	5,135	995	N/A	N/A	N/A
3/31/2022	5,294	1,196	941	1,223	N/A
12/31/2021	5,309	1,268	N/A	N/A	N/A
9/30/2021	5,350	1,424	1,127	1,374	N/A
6/30/2021	5,325	1,500	N/A	N/A	N/A
3/31/2021	5,018	1,459	1,434	1,630	N/A
12/31/2020	4,820	1,459	N/A	N/A	N/A
9/30/2020	4,569	1,364	978	1,472	N/A
6/30/2020	4,481	1,301	N/A	N/A	N/A
3/31/2020	4,440	1,293	904	1,409	N/A
12/31/2019	4,480	1,302	N/A	N/A	N/A
9/30/2019	4,366	1,210	1,147	1,276	N/A
6/30/2019	4,288	1,148	N/A	N/A	N/A
3/31/2019	4,220	1,111	N/A	1,286	N/A
12/31/2018	4,194	1,061	N/A	N/A	N/A
9/30/2018	4,261	1,068	N/A	N/A	N/A
6/30/2018	4,199	1,039	N/A	N/A	N/A
3/31/2018	3,918	901	N/A	1,160	N/A
12/31/2017	3,660	837	N/A	N/A	N/A
9/30/2017	3,213	725	N/A	N/A	N/A
6/30/2017	3,127	793	N/A	N/A	N/A
3/31/2017	3,290	915	N/A	1,074	N/A
12/31/2016	3,260	942	N/A	N/A	N/A
9/30/2016	3,404	998	N/A	N/A	N/A
6/30/2016	3,184	854	N/A	N/A	N/A
3/31/2016	2,938	759	N/A	934	N/A
3/31/2015	2,233	510	N/A	537	N/A

애널리스트 향후 성장 전망

수입 대 저축률: ADVENZYMES 의 연간 예상 수익 증가율(15%)이 saving rate(6.8%)보다 높습니다.

수익 vs 시장: ADVENZYMES 의 연간 수익(15%)이 Indian 시장(16.5%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: ADVENZYMES 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: ADVENZYMES 의 수익(연간 15.8%)이 Indian 시장(연간 10.9%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: ADVENZYMES 의 수익(연간 15.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: ADVENZYMES의 자본 수익률은 3년 후 12.1%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/11/20 07:18
종가	2025/11/20 00:00
수익	2025/09/30
연간 수익	2025/03/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Advanced Enzyme Technologies Limited는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Nandan Chakraborty	Axis Capital Limited
Abhishek Navalgund	Centrum Broking Limited
null null	DBS Bank Ltd

Advanced Enzyme Technologies 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Price target decreased to ₹265

Price target increased to ₹380

Recent updates

Advanced Enzyme Technologies Limited to Report Q2, 2026 Results on Nov 12, 2025

Preventive Health And Green Chemistry Will Expand Future Markets

Investor sentiment deteriorates as stock falls 15%

Here's What's Concerning About Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital

Insufficient new directors

Advanced Enzyme Technologies Limited to Report Q1, 2026 Results on Aug 02, 2025

Upcoming dividend of ₹1.20 per share

Full year 2025 earnings released: EPS: ₹11.72 (vs ₹11.92 in FY 2024)

Advanced Enzyme Technologies' (NSE:ADVENZYMES) Dividend Will Be ₹1.20

Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Due To Pay A Dividend Of ₹1.20

Dividend of ₹1.20 announced

Dividend of ₹4.00 announced

Advanced Enzyme Technologies Limited, Annual General Meeting, Jul 30, 2025

Is Advanced Enzyme Technologies (NSE:ADVENZYMES) A Risky Investment?

New major risk - Revenue and earnings growth

Third quarter 2025 earnings released: EPS: ₹3.36 (vs ₹3.74 in 3Q 2024)

Advanced Enzyme Technologies Limited to Report Q3, 2025 Results on Feb 08, 2025

Investor sentiment deteriorates as stock falls 22%

Second quarter 2025 earnings released: EPS: ₹2.94 (vs ₹3.08 in 2Q 2024)

New minor risk - Share price stability

Advanced Enzyme Technologies Limited to Report Q2, 2025 Results on Nov 09, 2024

Insider recently sold ₹51m worth of stock

Investor sentiment improves as stock rises 17%

After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar

Investor sentiment improves as stock rises 16%

First quarter 2025 earnings released: EPS: ₹3.05 (vs ₹2.58 in 1Q 2024)

Advanced Enzyme Technologies Limited to Report Q1, 2025 Results on Aug 10, 2024

Advanced Enzyme Technologies Approves Final Dividend for the Financial Year Ended March 31, 2024

We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now

Upcoming dividend of ₹1.10 per share

Full year 2024 earnings released: EPS: ₹11.92 (vs ₹9.45 in FY 2023)

Advanced Enzyme Technologies Limited, Annual General Meeting, Jul 25, 2024

Insider recently sold ₹11m worth of stock

Insider recently sold ₹6.9m worth of stock

Insider recently sold ₹6.9m worth of stock

Final dividend of ₹4.00 announced

Full year 2024 earnings released: EPS: ₹11.92 (vs ₹9.45 in FY 2023)

Advanced Enzyme Technologies Limited Recommends Final Dividend for the Financial Year 2023-2024

Advanced Enzyme Technologies Limited to Report Q4, 2024 Results on May 11, 2024

Advanced Enzyme Technologies Limited (NSEI:ADVENZYMES) acquired additional 5.89% stake in Jc Biotech Private Limited for INR 56.1 million

Third quarter 2024 earnings released: EPS: ₹3.74 (vs ₹2.63 in 3Q 2023)

Advanced Enzyme Technologies Limited to Report Q3, 2024 Results on Feb 10, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Advanced Enzyme Technologies Limited to Report Q2, 2024 Results on Nov 07, 2023

First quarter 2024 earnings released: EPS: ₹2.58 (vs ₹1.60 in 1Q 2023)

Advanced Enzyme Technologies Declares Final Dividend for the Financial Year Ended March 31, 2023

Advanced Enzyme Technologies Limited to Report Q1, 2024 Results on Aug 12, 2023

Upcoming dividend of ₹1.00 per share at 1.2% yield

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00

Advanced Enzyme Technologies Limited Proposes Dividend Payable on or After August 16, 2023

Insufficient new directors

Chairman recently bought ₹142m worth of stock

Chairman recently bought ₹2.7m worth of stock

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Advanced Enzyme Technologies Limited Announces Board Changes

Advanced Enzyme Technologies Limited to Report Q4, 2023 Results on May 13, 2023

Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business

Third quarter 2023 earnings released: EPS: ₹2.63 (vs ₹2.46 in 3Q 2022)

Advanced Enzyme Technologies Limited to Report Q3, 2023 Results on Feb 11, 2023

Advanced Enzyme Technologies Limited (BSE:540025) completed the acquisition of additional 4.83% stake in JC Biotech Private Limited.

Price target decreased to ₹265

Insider recently sold ₹100m worth of stock

Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends

Upcoming dividend of ₹1.00 per share

Full year 2022 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to ₹380

Third quarter 2022 earnings: EPS misses analyst expectations

Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital

Insider recently sold ₹611k worth of stock

Second quarter 2022 earnings released: EPS ₹2.66 (vs ₹3.33 in 2Q 2021)